Mayo Clinic Laboratories now offers an in-house ELISA assay to test for the presence of antibodies against myelin-associated glycoprotein (MAG) antibodies. In this episode of the “Answers From the Lab” podcast, John Mills, Ph.D., discusses how the semi-quantitative, calibrated assay uses unique, human MAG antigen that improves on earlier assays for detection of MAG antibodies. These antibodies are important biomarkers of the rare, hard-to-treat distal acquired demyelinating symmetric neuropathy (DADS). 

Although DADS can theoretically be diagnosed through clinical presentation and nerve conduction studies, those finding are less straightforward in practice, says Dr. Mills. “They are complex and heterogenous, and this partly explains why there tends to be a two- to three-year lag in these patients from the time they present with the neuropathy until they formally are diagnosed with DADs or MAG neuropathy.”

Listen to learn more about how incorporating MAG antibody testing into the diagnostic workup can help guide clinicians to the correct diagnosis earlier, equipping them with confidence about disease presence to guide treatment decisions.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MAGES | Myelin Associated Glycoproteins (MAG) Autoantibodies (IgM), Serum

Useful information

Evaluating peripheral neuropathy and paraproteinemic neuropathy.

Specimen requirements

• Container/Tube:
• Preferred: Red top
• Acceptable: Serum gel
• Specimen Volume: 1 mL

Performance information

• Analytic time: 1 day
• Day(s) and time(s) performed: Tuesdays and Fridays from 9AM to 5PM

The latest from Test in Focus

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less